Shares of Sellas Life Sciences (SLS) slid to $9.67 on November 1, extending a punishing 20%+ decline over five trading sessions as the company confirmed its pivotal late-stage cancer trial hit a critical milestone — but offered no hint of whether the drug actually works. Sellas Life Sciences' Billion-Dollar Bet on a Leukemia Drug Now Hangs on One Data Readout — Can the Stock Survive the Wait?
Shares of Sellas Life Sciences (SLS) sank to $9.67 on November 1 — down roughly 20% in five sessions — after the company announced its pivotal leukemia trial crossed a major threshold but revealed nothing about whether the drug actually works. For a company with zero revenue and a market capitalization that ballooned past $2 billion this year, the silence is deafening.
• The Trial Milestone Sounds Good, But the Market Is Selling the Uncertainty. On October 28, Sellas announced that its Phase 3 REGAL trial — testing a cancer immunotherapy called galinpepimut-S in patients with acute myeloid leukemia — reached the pre-specified 80th event (patient death), triggering final analysis.
The company remains blinded to efficacy results and expects preliminary topline data later this quarter. In plain terms: the trial collected enough data to run the final statistical test, but nobody — including Sellas management — knows the answer yet. SLS dropped roughly 16% on the announcement day alone.
• A $2 Billion Valuation Resting on a Coin Flip. The stock's 52-week range spans $1.39 to $15.88, and implied volatility sits at a staggering 171.8% — the options market is pricing in a massive move in either direction. Sellas generates $0 in revenue , meaning the entire valuation is a bet on this single readout. The company reported $138.3 million in cash as of June 30, 2026 , providing a financial cushion, but that's a fraction of its market value. A trial failure would likely wipe out most of the stock's 2026 gains.
• The Timeline Creates a Painful Waiting Game. Reaching the 80th event triggers database lock, unblinding, and statistical analysis, with management promising topline results by December 31, 2026. That leaves up to two months of information vacuum — an eternity for a binary biotech stock where bearish options flow has already been noted, with put volume running at three times normal levels.
• A Second Drug Offers a Partial Safety Net — But Only Partial. Beyond REGAL, Sellas has enrolled 28 of a planned 80 patients in a Phase 2 trial of a second drug candidate in newly diagnosed leukemia.
If both readouts hold their timelines, December could deliver verdicts on both programs within weeks. Still, the earlier-stage asset cannot offset a REGAL failure for a stock priced for success.
The math is stark: investors are paying over $2 billion for a pre-revenue company whose fate hinges on a single data release weeks away. Until those results arrive, every trading day is a referendum on conviction.